Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | The impact of CHIP in patients with AL amyloidosis

Giada Bianchi • 29 Sep 2023
IMS 2023
Amyloidosis Rare Diseases

Giada Bianchi, MD, Brigham and Women’s Hospital & Dana-Farber Cancer Institute, Boston, MA, discusses a study exploring the prevalence and impact of clonal hematopoiesis of indeterminate potential (CHIP) in patients with light chain (AL) amyloidosis. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Giada Bianchi

1:30
First-in-human study of autologous memory-like NK cells in patients with MRD+ multiple myeloma
Giada Bianchi • 29 Sep 2023
1:53
Novel laboratory-based therapeutic approach in AL amyloidosis: investigating FLC secretion
Giada Bianchi • 29 Sep 2023
1:48
Investigating the proteasome stress response as a potential novel therapeutic target in myeloma
Giada Bianchi • 29 Sep 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals